Display options
Cite
Wuertz KM, Barkei EK, Chen WH, et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters. bioRxiv. 2021;doi: 10.1101/2021.06.16.448525.
Wuertz, K. M., Barkei, E. K., Chen, W. H., Martinez, E. J., Lakhal-Naouar, I., Jagodzinski, L. L., Paquin-Proulx, D., Gromowski, G. D., Swafford, I., Ganesh, A., Dong, M., Zeng, X., Thomas, P. V., Sankhala, R. S., Hajduczki, A., Peterson, C. E., Kuklis, C., Soman, S., Wieczorek, L., Zemil, M., Anderson, A., Darden, J., Hernandez, H., Grove, H., Dussupt, V., Hack, H., de la Barrera, R., Zarling, S., Wood, J. F., Froude, J. W., Gagne, M., Henry, A. R., Mokhtari, E. B., Mudvari, P., Krebs, S. J., Pekosz, A. S., Currier, J. R., Kar, S., Porto, M., Winn, A., Radzyminski, K., Lewis, M. G., Vasan, S., Suthar, M., Polonis, V. R., Matyas, G. R., Boritz, E. A., Douek, D. C., Seder, R. A., Daye, S. P., Rao, M., Peel, S. A., Gordon Joyce, M., Bolton, D. L., Michael, N. L., & Modjarrad, K. (2021). A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.06.16.448525
Wuertz, Kathryn McGuckin, et al. "A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.06.16.448525
Wuertz KM, Barkei EK, Chen WH, Martinez EJ, Lakhal-Naouar I, Jagodzinski LL, Paquin-Proulx D, Gromowski GD, Swafford I, Ganesh A, Dong M, Zeng X, Thomas PV, Sankhala RS, Hajduczki A, Peterson CE, Kuklis C, Soman S, Wieczorek L, Zemil M, Anderson A, Darden J, Hernandez H, Grove H, Dussupt V, Hack H, de la Barrera R, Zarling S, Wood JF, Froude JW, Gagne M, Henry AR, Mokhtari EB, Mudvari P, Krebs SJ, Pekosz AS, Currier JR, Kar S, Porto M, Winn A, Radzyminski K, Lewis MG, Vasan S, Suthar M, Polonis VR, Matyas GR, Boritz EA, Douek DC, Seder RA, Daye SP, Rao M, Peel SA, Gordon Joyce M, Bolton DL, Michael NL, Modjarrad K. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters. bioRxiv. 2021 Jun 16; doi: 10.1101/2021.06.16.448525. PMID: 34159328; PMCID: PMC8219092.
Copy Download .nbib Format: NLM
Share it on

bioRxiv. 2021 Jun 16; doi: 10.1101/2021.06.16.448525.

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.

bioRxiv : the preprint server for biology

Kathryn McGuckin Wuertz, Erica K Barkei, Wei-Hung Chen, Elizabeth J Martinez, Ines Lakhal-Naouar, Linda L Jagodzinski, Dominic Paquin-Proulx, Gregory D Gromowski, Isabella Swafford, Akshaya Ganesh, Ming Dong, Xiankun Zeng, Paul V Thomas, Rajeshwer S Sankhala, Agnes Hajduczki, Caroline E Peterson, Caitlin Kuklis, Sandrine Soman, Lindsay Wieczorek, Michelle Zemil, Alexander Anderson, Janice Darden, Heather Hernandez, Hannah Grove, Vincent Dussupt, Holly Hack, Rafael de la Barrera, Stasya Zarling, James F Wood, Jeffrey W Froude, Matthew Gagne, Amy R Henry, Elham Bayat Mokhtari, Prakriti Mudvari, Shelly J Krebs, Andrew S Pekosz, Jeffrey R Currier, Swagata Kar, Maciel Porto, Adrienne Winn, Kamil Radzyminski, Mark G Lewis, Sandhya Vasan, Mehul Suthar, Victoria R Polonis, Gary R Matyas, Eli A Boritz, Daniel C Douek, Robert A Seder, Sharon P Daye, Mangala Rao, Sheila A Peel, M Gordon Joyce, Diane L Bolton, Nelson L Michael, Kayvon Modjarrad

PMID: 34159328 PMCID: PMC8219092 DOI: 10.1101/2021.06.16.448525

Abstract

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the B.1.1.7 and B.1.351 VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) immunogen dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose two vaccinations. SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.

References

  1. Expert Rev Vaccines. 2020 Mar;19(3):279-292 - PubMed
  2. Nat Med. 2021 Apr;27(4):622-625 - PubMed
  3. N Engl J Med. 2021 Jun 10;384(23):2212-2218 - PubMed
  4. Clin Infect Dis. 2020 Dec 3;71(9):2428-2446 - PubMed
  5. Nature. 2021 Feb;590(7844):E25 - PubMed
  6. Nature. 2020 Jul;583(7818):834-838 - PubMed
  7. Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595 - PubMed
  8. J Exp Med. 2021 Mar 1;218(3): - PubMed
  9. Nat Med. 2020 Nov;26(11):1694-1700 - PubMed
  10. Science. 2020 Aug 14;369(6505):806-811 - PubMed
  11. Cell. 2020 Apr 16;181(2):271-280.e8 - PubMed
  12. Nature. 2021 May;593(7857):130-135 - PubMed
  13. MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99 - PubMed
  14. Cell. 2021 Apr 29;184(9):2372-2383.e9 - PubMed
  15. N Engl J Med. 2020 Oct 15;383(16):1544-1555 - PubMed
  16. Nature. 2021 Apr;592(7854):438-443 - PubMed
  17. Nature. 2020 Oct;586(7830):509-515 - PubMed
  18. Cell. 2021 Apr 1;184(7):1804-1820.e16 - PubMed
  19. Cell. 2021 Apr 29;184(9):2316-2331.e15 - PubMed
  20. Cell Mol Immunol. 2021 Apr;18(4):1061-1063 - PubMed
  21. Nature. 2020 Oct;586(7830):583-588 - PubMed
  22. Nat Rev Microbiol. 2021 Mar;19(3):141-154 - PubMed

Publication Types